CoChat

Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial reported that intensive glucose control prevents end-stage kidney disease (ESKD) in patients with type 2 diabetes, but uncertainty about the balance between risks and benefits exists. Here, we examine the long-term effects of intensive glucose control on risk of ESKD and other outcomes. RESEARCH DESIGN AND METHODS: Survivors, previously randomized to intensive or standard glucose control, were invited to participate in post-trial follow-up. ESKD, defined as the need for dialysis or kidney transplantation, or death due to kidney disease, was documented overall and by baseline CKD stage, along with hypoglycemic episodes, major cardiovascular events, and death from other causes. RESULTS: A total of 8,494 ADVANCE participants were followed for a median of 5.4 additional years. In-trial HbA1c differences disappeared by the first post-trial visit. The in-trial reductions in the risk of ESKD (7 vs. 20 events, hazard ratio [HR] 0.35, P = 0.02) persisted after 9.9 years of overall follow-up (29 vs. 53 events, HR 0.54, P < 0.01). These effects were greater in earlier-stage CKD (P = 0.04) and at lower baseline systolic blood pressure levels (P = 0.01). The effects of glucose lowering on the risks of death, cardiovascular death, or major cardiovascular events did not differ by levels of kidney function (P > 0.26). CONCLUSIONS: Intensive glucose control was associated with a long-term reduction in ESKD, without evidence of any increased risk of cardiovascular events or death. These benefits were greater with preserved kidney function and with well-controlled blood pressure.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc15-2322

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 240

Metadata

Authors
Wong, M. G., Perkovic, V., Chalmers, J., Woodward, M., Li, Q., Cooper, M. E., Hamet, P., Harrap, S., Heller, S., MacMahon, S., Mancia, G., Marre, M., Matthews, D., Neal, B., Poulter, N., Rodgers, A., Williams, B., & Zoungas, S.
Affiliations
  • The University of Sydney (AU)
  • Baker Heart and Diabetes Institute (AU)
  • Centre Hospitalier de l’Université de Montréal (CA)
  • The Royal Melbourne Hospital (AU)
  • National Health Service (GB)
  • IRCCS Istituto Auxologico Italiano (IT)
  • Hôpital Bichat-Claude-Bernard (FR)
  • University of Oxford (GB)
  • Imperial College London (GB)
  • University College London (GB)
Corresponding author
Perkovic, Vlado
Venue
Diabetes Care
Published
2016-03-22
Volume
39
Issue
5
Pages
694-700
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2309242694
Cited by
240
References
19
Citations by year
2026: 12 · 2025: 15 · 2024: 19 · 2023: 23 · 2022: 28 · 2021: 27 · 2020: 23 · 2019: 21 · 2018: 37 · 2017: 24 · 2016: 11
FWCI
31.11
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion)
Funders
  • National Institute for Health and Care Research (NF-SI-0509-10222, NF-SI-0514-10011)
  • Medical Research Council (MC_PC_13090)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
tight glycemic control, end-stage renal disease, type 2 diabetes, ADVANCE trial, post-trial follow-up, chronic kidney disease, HbA1c, hypoglycemia, cardiovascular events, cardiovascular mortality, blood pressure, long-term outcomes
MeSH terms
Aged, Antihypertensive Agents, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Drug Combinations, Female, Follow-Up Studies, Gliclazide, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Indapamide, Kidney Failure, Chronic, Male, Middle Aged, Treatment Outcome, Perindopril

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.